Hybio Pharmaceutical Co., Ltd. (300199.SZ)
CNY 13.0
(4.17%)
CNY 13.0
(4.17%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -513.87 Million CNY | -38.68% |
| 2022 | -370.55 Million CNY | -1302.78% |
| 2021 | 30.8 Million CNY | 105.06% |
| 2020 | -609.42 Million CNY | 31.12% |
| 2019 | -884.77 Million CNY | -159.63% |
| 2018 | -340.77 Million CNY | -203.35% |
| 2017 | 329.72 Million CNY | 12.95% |
| 2016 | 291.92 Million CNY | -4.39% |
| 2015 | 305.34 Million CNY | 77.98% |
| 2014 | 171.56 Million CNY | 32.04% |
| 2013 | 129.93 Million CNY | 44.69% |
| 2012 | 89.79 Million CNY | 11.59% |
| 2011 | 80.47 Million CNY | 52.28% |
| 2010 | 52.84 Million CNY | 49.43% |
| 2009 | 35.36 Million CNY | 78.09% |
| 2008 | 19.85 Million CNY | 30.37% |
| 2007 | 15.23 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -14.1 Million CNY | 95.77% |
| 2024 Q2 | 3.74 Million CNY | 126.54% |
| 2024 Q3 | -24.44 Million CNY | -753.1% |
| 2023 Q3 | -146.41 Million CNY | -177.62% |
| 2023 FY | -513.87 Million CNY | -38.68% |
| 2023 Q2 | -52.73 Million CNY | -383.46% |
| 2023 Q4 | -333.32 Million CNY | -127.66% |
| 2023 Q1 | 18.6 Million CNY | 108.31% |
| 2022 Q1 | -57.65 Million CNY | -138.73% |
| 2022 Q4 | -223.76 Million CNY | -360.82% |
| 2022 Q3 | -48.55 Million CNY | -19.7% |
| 2022 FY | -370.55 Million CNY | -1302.78% |
| 2022 Q2 | -40.56 Million CNY | 29.64% |
| 2021 Q3 | -91.45 Million CNY | -82.62% |
| 2021 Q1 | 23.46 Million CNY | 103.53% |
| 2021 Q2 | -50.08 Million CNY | -313.42% |
| 2021 Q4 | 148.87 Million CNY | 262.79% |
| 2021 FY | 30.8 Million CNY | 105.06% |
| 2020 FY | -609.42 Million CNY | 31.12% |
| 2020 Q4 | -665.33 Million CNY | -7655.15% |
| 2020 Q3 | 8.8 Million CNY | -64.31% |
| 2020 Q2 | 24.67 Million CNY | 10.07% |
| 2020 Q1 | 22.42 Million CNY | 102.79% |
| 2019 Q4 | -804.72 Million CNY | -413.49% |
| 2019 FY | -884.77 Million CNY | -159.63% |
| 2019 Q1 | 52.05 Million CNY | 108.21% |
| 2019 Q2 | 24.61 Million CNY | -52.72% |
| 2019 Q3 | -156.71 Million CNY | -736.67% |
| 2018 Q2 | 111.56 Million CNY | 13.55% |
| 2018 Q1 | 98.24 Million CNY | 3.02% |
| 2018 FY | -340.77 Million CNY | -203.35% |
| 2018 Q4 | -634.35 Million CNY | -857.29% |
| 2018 Q3 | 83.76 Million CNY | -24.92% |
| 2017 Q3 | 74.11 Million CNY | -9.38% |
| 2017 FY | 329.72 Million CNY | 12.95% |
| 2017 Q2 | 81.78 Million CNY | 4.24% |
| 2017 Q1 | 78.45 Million CNY | 26.93% |
| 2017 Q4 | 95.36 Million CNY | 28.68% |
| 2016 Q3 | 119.47 Million CNY | 129.64% |
| 2016 FY | 291.92 Million CNY | -4.39% |
| 2016 Q2 | 52.02 Million CNY | -11.24% |
| 2016 Q1 | 58.61 Million CNY | -55.29% |
| 2016 Q4 | 61.81 Million CNY | -48.26% |
| 2015 Q3 | 84.56 Million CNY | 62.77% |
| 2015 Q4 | 131.09 Million CNY | 55.03% |
| 2015 Q1 | 37.73 Million CNY | -43.09% |
| 2015 Q2 | 51.95 Million CNY | 37.69% |
| 2015 FY | 305.34 Million CNY | 77.98% |
| 2014 Q3 | 55.91 Million CNY | 100.87% |
| 2014 Q4 | 66.3 Million CNY | 18.58% |
| 2014 Q2 | 27.83 Million CNY | 29.41% |
| 2014 Q1 | 21.51 Million CNY | -64.29% |
| 2014 FY | 171.56 Million CNY | 32.04% |
| 2013 Q3 | 28.01 Million CNY | 18.3% |
| 2013 Q1 | 17.98 Million CNY | -35.02% |
| 2013 Q2 | 23.68 Million CNY | 31.72% |
| 2013 Q4 | 60.24 Million CNY | 115.01% |
| 2013 FY | 129.93 Million CNY | 44.69% |
| 2012 Q4 | 27.67 Million CNY | 15.2% |
| 2012 Q1 | 15.64 Million CNY | -47.56% |
| 2012 FY | 89.79 Million CNY | 11.59% |
| 2012 Q2 | 22.45 Million CNY | 43.56% |
| 2012 Q3 | 24.02 Million CNY | 6.96% |
| 2011 Q1 | 12.75 Million CNY | -43.12% |
| 2011 Q2 | 17.31 Million CNY | 35.77% |
| 2011 Q3 | 20.58 Million CNY | 18.88% |
| 2011 Q4 | 29.83 Million CNY | 44.94% |
| 2011 FY | 80.47 Million CNY | 52.28% |
| 2010 FY | 52.84 Million CNY | 49.43% |
| 2010 Q1 | 2.51 Million CNY | 0.0% |
| 2010 Q3 | 11.63 Million CNY | -28.57% |
| 2010 Q2 | 16.28 Million CNY | 547.64% |
| 2010 Q4 | 22.41 Million CNY | 92.72% |
| 2009 FY | 35.36 Million CNY | 78.09% |
| 2008 FY | 19.85 Million CNY | 30.37% |
| 2007 FY | 15.23 Million CNY | 0.0% |